Wells Fargo & Company Sigilon Therapeutics, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.34 - $1.38 $0 - $1	1 Added 0.98%	103 $0
Q4 2022 Feb 13, 2023	BUY	$0.29 - $0.69 $0 - $2	3 Added 3.03%	102 $0
Q3 2022 Nov 14, 2022	BUY	$0.48 - $0.86 $0 - $0	1 Added 1.02%	99 $0
Q2 2022 Aug 12, 2022	SELL	$0.74 - $1.64 $6,568 - $14,558	-8,877 Reduced 98.91%	98 $0
Q1 2022 May 16, 2022	SELL	$1.24 - $3.03 $6,604 - $16,137	-5,326 Reduced 37.24%	8,975 $13,000
Q4 2021 Feb 14, 2022	SELL	$2.58 - $6.13 $188,551 - $447,992	-73,082 Reduced 83.63%	14,301 $39,000
Q3 2021 Nov 15, 2021	BUY	$4.42 - $10.61 $313,669 - $752,949	70,966 Added 432.27%	87,383 $494,000
Q2 2021 Aug 16, 2021	BUY	$9.15 - $20.17 $128,173 - $282,541	14,008 Added 581.49%	16,417 $176,000
Q1 2021 May 13, 2021	BUY	$18.76 - $40.91 $45,192 - $98,552	2,409 New	2,409 $54,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.